O bstructive sleep apnea syndrome (OSAS) is a common breathing-related sleep disorder caused by repeated narrowing of the throat during sleep, and the airways can be either partially or completely blocked during OSAS. 1 Recent studies show the association of OSAS with cardiovascular disease (CVD). 2 Prospective community-based studies have demonstrated that men with untreated severe OSAS had an increased risk for all-cause and cardiovascular mortality that was independent of traditional CVD risk factors. [3] [4] [5] The
Sleep Heart Health Study found that incidence of stroke, 6 coronary heart disease, 7 and heart failure 7 increased in persons with severe OSAS. A recent meta-analysis further confirmed that the risk of all-cause mortality increased in patients with severe OSAS compared with persons without OSAS. 8 The mechanisms underlying OSAS-associated CVD are not fully understood. Several factors, such as endothelial dysfunction, arterial stiffening, and systemic inflammation, may mediate OSAS-associated CVD. Endothelial dysfunction contributes substantially to the pathogenesis of cardiovascular disorders. [9] [10] [11] Arterial stiffening is strongly associated with the development of atherosclerosis. 12 Epidemiological studies have demonstrated that high arterial stiffness is associated with increased risk of CVD and cardiovascular events. [13] [14] [15] In addition, increasing evidence suggests that inflammation plays an important role in the development of cardiovascular complications in patients with OSAS. 16, 17 High-sensitivity C-reactive protein/C-reactive protein (hsCRP/CRP), a member of the pentraxin protein family, 18 can mediate atherosclerosisassociated low-grade inflammation and is a product of the inflammatory reaction. 19 Increased serum level of hsCRP/CRP is an independent risk predictor for CVD. 20, 21 The proinflammatory cytokine tumor necrosis factor a (TNF-a) plays an essential role in host defense and mediates the pathogenesis of atherosclerosis. 22 Elevated TNF-a levels predict the incidence of fatal and nonfatal cardiovascular events, such as heart failure and acute coronary syndrome. 17, 23 Nevertheless, the effects of OSAS on endothelial dysfunction, arterial stiffening, and systemic inflammation are still unclear.
In a previous meta-analysis, although serum inflammatory markers were investigated in patients with OSAS, 24 the authors did not conduct metaregression to analyze the effects of potential modifiers, such as systolic and diastolic blood pressures, on the study end points. Systolic and diastolic blood pressures have been found to be associated with elevated inflammatory markers. 25 The purpose of this metaanalysis was to investigate the impact of OSAS on endothelial function, arterial stiffening, and serum levels of inflammatory markers hsCRP/CRP and TNF-a and to examine the impact of potential modifiers on the effects of OSAS on the markers representing endothelial function, arterial stiffening, and inflammation. The findings of this study might shed new light on the mechanisms underlying OSAS-associated CVD.
Materials and Methods

Guidelines and Data Collection
This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines. 26 Computerized and manual searches for relevant English articles published within the past 10 years were conducted using the following 5 electronic literature databases: PubMed, Excerpta Medica Database, ISI Web of Science, Directory of Open Access Journals, and the Cochrane Library. The reference lists of the retrieved articles and abstracts of scientific conference proceedings ( Figure 1 ) were also manually searched. The Cochrane Database of Systematic Reviews and the Database of Abstracts of Reviews of Effectiveness were also searched to identify reviews that could lead to eligible trials.
Search Terms
The following search terms were used: ("sleep apnea" [ 
OSAS Definition, Study End Points, and Measurements
The apnea-hypopnea index (AHI) was defined as the average number of episodes of apneas and hypopneas per hour of sleep. OSAS was defined in events per hour as AHI ≥5. Participants were categorized into the following 4 subgroups according to their AHI values: healthy persons (AHI <5) and patients with OSAS that was mild (AHI 5 to <15), moderate (AHI 15 to <30), or severe (AHI ≥30). Moderate-severe OSAS was defined as AHI ≥15; mild-moderate OSAS was defined as AHI 5 to <30. The primary end point was the difference in serum levels of CRP and TNF-a, arterial stiffness, and vascular endothelial function between patients with OSAS and controls. The control group included persons without OSAS. Endothelial function was evaluated by brachial artery dilatation in response to hyperemia (represented by flowmediated dilation [FMD]) or nitroglycerin (NTG; represented by NTG-induced dilation), which was calculated as the percentage change in arterial diameter on stimulation relative to resting values. Arterial stiffness was determined by carotidfemoral pulse wave velocity (PWV), which reflects the amount of time that the pulse wave generated by the contracting heart needs to travel to the periphery and to be reflected back. 2, 27 Augmentation index (AIx) was also determined to estimate arterial stiffness. The inflammatory response in patients was evaluated by serum levels of hsCRP/CRP and TNF-a. The definition and units of the indices of endothelial function, arterial stiffness, and inflammatory markers are displayed in Table 1 .
Data Extraction and Quality Assessment
Two reviewers (J.W and W.Y.) extracted the following information from the eligible studies independently: first author's surname, year of publication, country of origin, study design, sample size of OSAS and control groups, means and standard deviations of FMD, NTG-induced dilation, carotid-femoral PWV, AIx, and serum levels of hsCRP/CRP and TNF-a in both groups. If studies contained multiple categories of OSAS or body mass index (BMI), data were extracted at each category as independent studies. The 11 items recommended by the US Agency for Healthcare Research and Quality (AHRQ) for assessing the quality of cross-sectional studies were used to assess the quality of the included studies. 28 
Study Inclusion and Exclusion Criteria
Studies with a focus on the investigation of the association of OSAS with serum levels of inflammatory markers (hsCRP/ CRP and TNF-a), endothelial function, and arterial stiffening were included. The following exclusion criteria were used: (1) duplicate publication; (2) report in the format of an abstract, review, comment, or editorial; (3) preclinical study; (4) lack of sufficient original data; (5) lack of a control group; (6) patients with OSAS and aged <18 years; (7) patient inclusion criteria in the report explicitly describing that patients with OSAS had traditionally known diseases, including hypertension, diabetes, dyslipidemia, cardiovascular diseases, neuromuscular diseases, inflammatory diseases, restrictive pulmonary disease, chronic renal disease, and/or were taking antihypertensive, antidiabetic, lipidlowering, antidepressant, or anti-inflammation medication; (8) study participants in the report were patients with OSAS and obesity.
Statistical Analysis
Standardized mean differences (SMDs) with 95% CIs of FMD, NTG-induced dilation, carotid-femoral PWV, AIx, and serum levels of hsCRP/CRP and TNF-a in patients with OSAS compared with those in the control group were calculated. The inverse variance method was used to estimate the weight of each study for SMD calculation. A Z test was performed to determine the statistical significance of SMDs. Study heterogeneity was evaluated by Cochran's Q test and the I 2 index.
P<0.10 in the Q test was considered significantly heterogeneous. A fixed-effects model was used when study heterogeneity was not significant; a random-effects model was used when study heterogeneity was significant. When significant study heterogeneity was detected, metaregression was conducted to explore the association between predictor variables and SMD, in other words, to examine whether the impact of OSAS on FMD, NTG-induced dilation, carotid-femoral PWV, CRP/hsCRP, and TNF-a could be modified by potentially meaningful predictors, such as demographic parameters, blood pressure, and blood lipid profile. A Q model statistic was used to estimate the association. Funnel plot and Egger's linear regression test were used to estimate publication bias.
All P values are 2-sided. All statistical analyses were conducted using the Stata statistical analysis software (version 13.0; Stata Corp). 
Results
Study Characteristics and Quality Assessment
The flow diagram of study selection is displayed in Figure 1 . [29] [30] [31] [32] [34] [35] [36] 38, 39 5 reported the impact of OSAS per se on arterial stiffening (determined by carotid-femoral PWV and AIx), 36, 37, 39, 40, 42 and 7 investigated the effects of OSAS per se on serum inflammatory markers (hsCRP/CRP and TNF-a). 18, 31, 33, 41, [43] [44] [45] The ARHQ methodology checklist of quality assessment of the included cross-sectional studies is displayed in Table 3 . All included cross-sectional studies described the source of data and patient inclusion and exclusion criteria clearly, provided detailed explanation for excluded data, and presented multiple measurements for the primary study end points.
Patients With Moderate-Severe OSAS Showed Significantly Lower FMD Than Controls
The Q-statistic (P<0.0001) test and the I 2 index (74.8%) demonstrated significant heterogeneity of the eligible studies; therefore, a random-effects model was used to calculate the SMD of FMD. The analysis revealed that FMD in patients with OSAS was significantly lower than that in controls (SMD À1.21, 95% CI À1.60 to À0.83, P<0.0001) ( Figure 2A ). Subgroup analysis of moderate-severe OSAS (AHI ≥15) showed that patients with moderate-severe OSAS had significantly lower FMD than controls (SMD À1.02, 95% CI À1.31 to À0.73, P<0.0001) ( Figure 2B ) without significant study heterogeneity (Q statistic P=0.154, I 2 =42.9%) and publication bias (P=0.243). In contrast to FMD, NTG-induced dilation was similar in the OSAS and control groups (SMD 0.11, 95% CI À0.22 to 0.44, P=0.306) ( Figure 2C ) without significant heterogeneity (Q statistic P=0.164, I 2 =44.7%) and publication bias (P=0.856).
Patients With OSAS Showed Significantly Higher Carotid-Femoral PWV and AIx Than Controls
Carotid-femoral PWV was significantly higher in patients with OSAS than in controls (SMD 0.45, 95% CI 0.21-0.69, P<0.0001) ( Figure 3A ) without significant study heterogeneity (I 2 =47.3%, P=0.108) and publication bias (P=0.830). Similarly, subgroup analysis also demonstrated significantly higher carotid-femoral PWV in patients with moderate-severe OSAS (SMD 0.55, 95% CI 0.27-0.84, P<0.0001) ( Figure 3B ) without significant study heterogeneity (I 2 =46.4%, P=0.133). Consistently, AIx, which also indicates arterial stiffness, was significantly higher in patients with OSAS than in controls (SMD 0.57, 95% CI 0.25-0.90, P<0.0001) ( Figure 3C ) without study heterogeneity (I 2 =0.0%, P=0.826).
Patients With OSAS Showed Significantly Higher Serum Levels of hsCRP/CRP and TNF-a Than Controls
Serum levels of hsCRP/CRP were significantly higher in patients with OSAS than in controls (SMD 0.58, 95% CI 0.42-0.73, P<0.0001) ( Figure 4A ) without significant study heterogeneity (I 2 =28.6%, P=0.173) and publication bias (P=0.468). Subgroup analysis of isolated hsCRP (SMD 0.71, 95% CI 0.49-0.92, P<0.0001) ( Figure 4A ) and isolated CRP (SMD 0.43, 95% CI 0.20-0.66, Z=3.69, P<0.0001) ( Figure 4A ) consistently showed significantly higher levels of the inflammatory markers in patients with OSAS. In addition to hsCRP/CRP, serum levels of TNF-a were also significantly higher in patients with OSAS than in controls (SMD 1.29, 95% CI 0.25-2.33, P<0.0001) ( Figure 4B ) without significant publication bias (P=0.906) but with significant study heterogeneity (I 2 =91.9%, P<0.0001). The source of heterogeneity might be associated with OSAS severity. Because of the small number of eligible studies, we were unable to perform subgroup analysis of TNF-a in patients with moderatesevere OSAS. (2) CAD (3) valvulopathy, permanent atrial fibrillation or congenital heart disease (4) hypertension, diabetes, dyslipidemia, drug treatment and (5) A, Carotid-femoral PWV was significantly higher in patients with OSAS than in controls. B, Carotid-femoral PWV was significantly higher in patients with moderate-severe OSAS than in controls. C, Augmentation index was significantly higher in patients with moderate-severe OSAS than in controls. ID indicates identifier; OSAS, obstructive sleep apnea syndrome; PWV, pulse wave velocity; SMD, standardized mean differences.
Metaregression Analysis of the Potential Modifiers
We performed metaregression to examine the impact of potential modifiers on OSAS-related changes in FMD, NTGinduced dilation, carotid-femoral PWV, CRP/hsCRP, and TNF-a. A total of 14 covariates-mean age, proportion of men, systolic and diastolic blood pressures, smoking status, BMI, levels of total cholesterol, triglycerides (TG), fasting blood glucose, highand low-density lipoprotein, heart rate, Epworth sleepiness score, and publication year-were extracted from the included studies (Tables 4 and 5) . When all OSAS patients were included, BMI and TG significantly modified the impact of OSAS on FMD (both P<0.05) ( Table 4 ), suggesting that different BMI and TG in patients with OSAS may be a source of study heterogeneity for the meta-analysis of FMD. The impact of OSAS on other markers, including NTG-induced dilation, carotid-femoral PWV, hsCRP/CRP, and TNF-a, were not affected by the 14 potential modifiers (Table 4) . Further examination of the relationship between the SMD of FMD and BMI and TG revealed that the difference in FMD between OSAS patients and controls increased as BMI increased ( Figure 5A ) and decreased as TG increased ( Figure 5B ). In the subgroup of patients with moderate-severe OSAS, none of the 14 covariates significantly modified the impact of OSAS on FMD and carotid-femoral PWV (Table 5) . Consequently, the result showing that patients with moderate-severe OSAS had significantly lower FMD than controls was not influenced by the potential modifiers. We were unable to perform metaregression to analyze the effects of potential modifiers on the study end point AIx because of the limited number of eligible studies.
Discussion
This updated meta-analysis demonstrated that patients with OSAS, particularly patients with moderate-severe OSAS, had significantly lower FMD and higher carotid-femoral PWV, AIx, and serum levels of hsCRP/CRP and TNF-a than controls. These findings suggest that OSAS might be associated with impaired endothelial function, arterial stiffening, and chronic systemic inflammation.
To the best of our knowledge, this meta-analysis is the first to investigate the impact of OSAS, per se, on endothelial function and arterial stiffening. All included studies were conducted in the past decade, reflecting the use of more recent guidelines. This meta-analysis eliminated studies that included patients with OSAS and concomitant traditionally known diseases, such as CVD and diabetes. To further examine whether the 14 potential modifiers could affect the study end points, we conducted metaregression. The metaregression results showed that BMI and TG significantly modified OSAS-related reduction in FMD but did not affect the impact of moderate-severe OSAS on FMD, suggesting that the association between moderate-severe OSAS and endothelial dysfunction appears to be independent of BMI; however, the influence of mild OSAS on endothelial function may be complicated by other factors, such as obesity and high TG. Nevertheless, metaregression also showed that BMI and the other 13 potential modifiers did not modify OSASrelated changes in markers representing arterial stiffening and inflammation. Because arterial stiffening and inflammation are also associated with endothelial dysfunction, OSAS may still contribute to vascular dysfunction, although obesity may play a role in endothelial dysfunction in patients with OSAS.
The vascular endothelium, an active monolayer of cells, is involved in the regulation of vasodilation. 46 Endothelial cells can produce nitric oxide to protect vessels from atherosclerosis by promoting local vasodilatation and inhibiting platelet aggregation, monocyte adhesion, and vascular smooth muscle proliferation. 47 Consequently, endothelial dysfunction is often considered one of the earliest detectable and possibly reversible abnormalities during the development of atherosclerosis. The metaregression results of this current study and of previous studies suggest that the correlation of OSAS with endothelial dysfunction may depend on the severity of OSAS.
In a cross-sectional study of a cohort of men with OSAS (AHI 15-50) and CVD, Seif et al found that patients with an oxygen desaturation index ≥24.6 showed declining endothelial function, whereas for patients with an oxygen desaturation index between 13.9 and 24.6, there was a positive correlation between increasing oxygen desaturation index and endothelial function. 48 This finding suggests that mild to moderate OSAS may trigger some protective mechanisms against CVD, but moderate to severe OSAS appears to be associated with endothelial dysfunction. 49 The Sleep Heart Health Study consistently demonstrated that increased incidence of mortality, stroke, coronary artery disease, and heart failure was associated with moderate-severe OSAS. [5] [6] [7] Other crosssectional data of population-based studies also showed an association between severe OSAS and impaired endothelial function. Chung et al found that reduced FMD was significantly associated with severe OSAS. 31 Our results also showed that patients with moderate-severe OSAS had significantly lower FMD than the controls, indicating endothelial dysfunction in patients with moderate-severe OSAS. These findings suggest that moderate-severe OSAS appears to independently contribute to endothelial dysfunction, leading to OSAS-mediated CVD; however, whether mild OSAS can damage endothelial function remains to be determined.
In addition, this current study showed that patients with OSAS, particularly patients with moderate-severe OSAS, had significantly lower FMD but similar NTG-induced dilation compared with controls. NTG-induced dilation has been used to evaluate vascular smooth muscle function. 50 After entering vascular smooth muscle cells, NTG can trigger a series of events, including conversion of nitrate to nitric oxide, activation of soluble guanylate cyclase, synthesis of cyclic guanosine monophosphate, and reduction of cytosolic calcium levels, ultimately leading to smooth muscle relaxation. 51 Reduced Figure 4 . The impact of obstructive sleep apnea on serum inflammatory markers. A, The serum levels of hsCRP/CRP were significantly higher in patients with OSAS than in controls. B, The serum levels of TNF-a were significantly higher in patients with OSAS than in controls. CRP indicates C-reactive protein; hsCRP, high-sensitivity C-reactive protein; OSAS, obstructive sleep apnea syndrome; SMD, standardized mean differences; TNF-a, tumor necrosis factor a.
FMD and similar NTG-induced dilation in patients with OSAS compared with controls indicate that patients with OSAS have endothelial dysfunction, although their vascular smooth muscle function is normal. The effects of OSAS on vascular smooth muscle function need to be investigated further. Arterial stiffness, which can be measured by AIx and carotid-femoral PWV, has been recognized as a cumulative indicator of vascular health. 15 Compared with AIx (representing wave reflection), carotid-femoral PWV (measuring arterial stiffness in the large, elastic, central arteries) is more often used to predict cardiovascular events in general and morbid populations. 2 Reports by others showed inconsistent results regarding the association of OSAS with the changes in carotid-femoral PWV. Bruno et al found that significantly increased carotid-femoral PWV was observed only in patients with OSAS and concomitant traditional cardiovascular risk factors, whereas patients with OSAS only had levels of carotid-femoral PWV similar to healthy persons. 39 In contrast, in a prospective controlled study, Buchner et al found that OSAS was independently associated with increased arterial stiffening and treatment with continuous positive airway pressure significantly reduced arterial stiffening. 52 Chung et al demonstrated that carotid-femoral PWV was significantly higher in patients with severe OSAS than in patients with mild to moderate OSAS or in healthy controls. 36 In this current study, we found that both carotid-femoral PWV and AIx were significantly increased in patients with OSAS, indicating that patients with OSAS may suffer a higher extent of arterial stiffening. Arterial stiffening has been indicated to play a role in the development of systemic hypertension, cardiac systolic and diastolic dysfunction, pulmonary hypertension, and cardiac ischemia, leading to cardiovascular morbidity and mortality in patients with OSAS. 27, 53, 54 This current meta-analysis also showed that the serum levels of inflammatory markers, including hsCRP/CRP and TNF-a, were increased in patients with OSAS. Numerous studies have demonstrated that serum level of hsCRP/CRP is a strong predictor of future cardiovascular events. 18, 20, 55 Ciccone et al found a significant correlation between carotid intima-media thickness and the inflammatory markers, hsCRP, IL-6, TNF-a, and pentraxin-3 in patients with OSAS. 45 They also showed that hsCRP and TNF-a levels were independent predictors of carotid intima-media thickness values. 45 Increased carotid intima-media thickness is a risk factor for early atherosclerosis development and CVD. 56, 57 Pathophysiological mechanisms underlying the association of hsCRP/CRP and cardiovascular disturbances, such as atherosclerosis, have been investigated. 45 HsCRP, which is found in atherosclerotic plaque, 58 can induce the secretion of inflammatory factors from vascular endothelium, 59 stimulate the expression of adhesion molecules, 60 and opsonize lowdensity lipoproteins for macrophage uptake to facilitate lowdensity lipoprotein deposition on vessel walls. 61 Whether OSAS, per se, can increase serum CRP levels remains inconclusive and requires further investigation. Sharma et al found that in patients with OSAS, obesity but not OSAS was associated with elevated serum levels of CRP, and there was no independent correlation between the severity of OSAS and serum levels of CRP. 62 In contrast,
Guven et al showed that OSAS was a potential factor for increased CRP levels regardless of BMI. 18 The metaregression of this current study showed that BMI did not modify the impact of OSAS or moderate-severe OSAS on serum levels of hsCRP/CRP. Furthermore, this current meta-analysis demonstrated that serum level of TNF-a was elevated in patients with OSAS; however, we were limited by the small number of eligible studies and were unable to further examine the correlation between OSAS severity and serum TNF-a level.
A possible correlation between the levels of inflammatory markers and CVD severity in patients with OSAS has been proposed. 17 The pathophysiological mechanisms underlying OSASmediated endothelial dysfunction, arterial stiffening, and elevated serum levels of inflammatory markers may be related to OSAS-induced intermittent hypoxia. Intermittent hypoxia has been found to increase the production of reactive oxygen species, consequently increasing oxidative stress, and prolonged oxidative stress can reduce the enzymatic activity of endothelial nitric oxide synthase by blocking endothelial nitric oxide synthase phosphorylation at S1179. [63] [64] [65] Oxidative stress also reduces available substrates for nitric oxide synthesis. 66, 67 Reduced nitric oxide production results in endothelial dysfunction and arterial stiffening, ultimately increasing cardiovascular complications such as atherosclerosis in patients with OSAS. 32, 63, 68 Furthermore, intermittent hypoxia and sleep disturbances may cause chronic inflammation, increasing serum levels of CRP or other inflammatory markers and contributing to the development of atherosclerosis in patients with OSAS. 4, 19, 32 This study has some limitations. Although 14 potential modifiers that could affect the study end points were analyzed in the metaregression, untested OSAS-associated modifiers are complex and may still inevitably affect the results. The included studies were typical cross-sectional studies with small sample sizes. Other indicators for endothelial function, such as the levels of circulating endothelial progenitor cells, could not be used for the meta-analysis because of insufficient data and limited eligible studies. Moreover, different techniques and instruments were used for the measurement of FMD, PWV, and inflammatory markers, which could be another source of study heterogeneity.
Conclusions
Our findings suggest that OSAS, particularly moderate-severe OSAS, was significantly associated with impaired endothelial function, increased arterial stiffness, and elevated serum levels of inflammatory markers. The metaregression data suggest that the adverse effect of moderate-severe OSAS on endothelial function is not modified by potential covariates, such as BMI, and OSAS-associated arterial stiffening and systemic inflammation are not modified by potential covariates, including BMI and blood lipid profile. Consequently, OSAS-particularly moderate-severe OSAS-may contribute to CVD development by causing endothelial dysfunction, arterial stiffening, and systemic chronic inflammation.
